Cargando…

EHMTI-0326. OnabotulinumtoxinA for the treatment of chronic paroxysmal hemicrania: a case report

Detalles Bibliográficos
Autor principal:	Dolezil, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179927/ http://dx.doi.org/10.1186/1129-2377-15-S1-C16

Ejemplares similares

EHMTI-0286. Hemicrania epileptica: case report
por: Traverso, F, et al.
Publicado: (2014)

OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients
por: Miller, Sarah, et al.
Publicado: (2015)

EHMTI-0278. Onabotulinum toxin a for hemicrania continua: a case series of 8 patients
por: Miller, S, et al.
Publicado: (2014)

EHMTI-0283. Predictors of early response to onabotulinumtoxin type a in chronic migraine
por: Mas-Sala, N, et al.
Publicado: (2014)

EHMTI-0105. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine
por: Cernuda-Morollón, E, et al.
Publicado: (2014)

EHMTI-0191. A novel approach for the treatment of cluster headache – onabotulinumtoxina block of the sphenopalatine ganglion
por: Bratbak, D, et al.
Publicado: (2014)

EHMTI-0257. Intractable refractory unilateral hemicrania with autonomic symptoms – a case study of an undiagnosed pontine cavernous malformation
por: Talibi, SS, et al.
Publicado: (2014)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union
por: Matharu, M, et al.
Publicado: (2014)

Paroxysmal Hemicrania
por: Osman, Chinar, et al.
Publicado: (2018)

EHMTI-0102. Prospective analysis of the use of onabotulinumtoxina (botox®) In the treatment of chronic migraine; real-life data in 299 patients from hull, UK
por: Khalil, M, et al.
Publicado: (2014)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
por: Lampl, Christian, et al.
Publicado: (2018)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Chronic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the three first described cases
por: Sjaastad, Ottar
Publicado: (2006)

Chronic paroxysmal hemicrania in paediatric age: report of two cases
por: Tarantino, Samuela, et al.
Publicado: (2011)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Successful treatment of indomethacin-intolerant chronic paroxysmal hemicrania: report of two cases
por: Rajabally, Yusuf A.
Publicado: (2003)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

EHMTI-0060. Neurosarcoidosis and chronic headache - case report
por: Vukojevic, Z
Publicado: (2014)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Case Report: Shortest Course of Pediatric Paroxysmal Hemicrania
por: Ishii, Ryotaro, et al.
Publicado: (2019)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

EHMTI-0037. Botulinum A toxin for treatment of chronic migraine
por: Grazzi, L, et al.
Publicado: (2014)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_abli1nuace69slceo6a8b814g5